Filipa Lynce, MD
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Filipa Lynce, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:10 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06488378 · Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast CancerDana-Farber Cancer Institute · recruiting · Breast Cancer, PALB2-Mutated Breast Carcinoma, HER2-negative Breast Cancer · principal investigator
- Ph1NCT06351332 · ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBCFilipa Lynce, MD · terminated · Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer · principal investigator
- Ph2NCT05795101 · TRUDI: TDXD+Durva in HER2+/Low IBCFilipa Lynce, MD · recruiting · Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer · principal investigator
- Ph1NCT03641755 · Olaparib + Sapacitabine in BRCA Mutant Breast CancerDana-Farber Cancer Institute · active not recruiting · Breast Cancer · principal investigator
- Ph2NCT02876302 · Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast CancerDana-Farber Cancer Institute · completed · Inflammatory Breast Cancer (IBC) · principal investigator
- Ph2NCT02623972 · A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast CancerDana-Farber Cancer Institute · active not recruiting · Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast · principal investigator
- Ph2NCT01796197 · Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCaDana-Farber Cancer Institute · completed · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.